Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope
Proceedings of the National Academy of Sciences · 23.01.2024 · 121 (4)
DOI: 10.1073/pnas.2317283121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 16.01.2024. Verfasst von X F Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, MD 20892. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCRR NIH HHS, HHS | NIH | National Cancer Institute.
Abstract (Originalsprache)
Despite many clinical trials, CAR-T cells are not yet approved for human solid tumor therapy. One popular target is mesothelin (MSLN) which is highly expressed on the surface of about 30% of cancers including mesothelioma and cancers of the ovary, pancreas, and lung. MSLN is shed by proteases that cleave near the C terminus, leaving a short peptide attached to the cell. Most anti-MSLN antibodies bind to shed MSLN, which can prevent their binding to target cells. To overcome this limitation, we developed an antibody (15B6) that binds next to the membrane at the protease-sensitive region, does not bind to shed MSLN, and makes CAR-T cells that have much higher anti-tumor activity than a CAR-T that binds to shed MSLN. We have now humanized the Fv (h15B6), so the CAR-T can be used to treat patients and show that h15B6 CAR-T produces complete regressions in a hard-to-treat pancreatic cancer patient derived xenograft model, whereas CAR-T targeting a shed epitope (SS1) have no anti-tumor activity. In these pancreatic cancers, the h15B6 CAR-T replicates and replaces the cancer cells, whereas there are no CAR-T cells in the tumors receiving SS1 CAR-T. To determine the mechanism accounting for high activity, we used an OVCAR-8 intraperitoneal model to show that poorly active SS1-CAR-T cells are bound to shed MSLN, whereas highly active h15B6 CAR-T do not contain bound MSLN enabling them to bind to and kill cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, MD 20892.
- Center for Advanced Preclinical Research, Frederick National Lab for Cancer Research Center for Cancer Research, National Cancer Institute, NIH, Frederick, MD 21701.
- Thoracic and Gastrointestinal Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20892.
Förderung
- NCRR NIH HHS
- HHS | NIH | National Cancer Institute
Zitieren
APA
Liu, X. F., Onda, M., Schlomer, J., Bassel, L., Kozlov, S., Tai, C. H., Zhou, Q., Liu, W., Tsao, H. E., Hassan, R., Ho, M., & Pastan, I. (2024). Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope. Proceedings of the National Academy of Sciences, 121(4). https://doi.org/10.1073/pnas.2317283121
Vancouver
Liu XF, Onda M, Schlomer J, Bassel L, Kozlov S, Tai CH, et al. Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope. Proceedings of the National Academy of Sciences. 2024;121(4). doi:10.1073/pnas.2317283121
BibTeX
@article{Liu2024,
author = {Liu, X F and Onda, M and Schlomer, J and Bassel, L and Kozlov, S and Tai, C-H and Zhou, Q and Liu, W and Tsao, H-E and Hassan, R and Ho, M and Pastan, I},
title = {Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
volume = {121},
number = {4},
doi = {10.1073/pnas.2317283121}
}
EUVIMED